logo-loader

Genprex forms Clinical Advisory Board to support its oncology and diabetes development programs

Last updated: 16:20 08 Feb 2021 EST, First published: 16:06 08 Feb 2021 EST

Genprex, Inc. - Genprex Inc forms Clinical Advisory Board to support its oncology and diabetes development programs as it advances its REQORSA immunogene therapy program
Two Acclaim trials will evaluate REQORSA in combination with AstraZeneca’s drug Tagrisso and Merck & Co’s Keytruda

Genprex Inc (NASDAQ:GNPX) announced Monday the formation of a Clinical Advisory Board (CAB) to support its oncology and diabetes development programs. 

Comprised of preeminent clinical specialists, the company said the CAB will lead and advise Genprex as it advances its REQORSA immunogene therapy program, including its Acclaim clinical trials in non-small cell lung cancer, and its preclinical diabetes gene therapy program. Some of the members also serve in additional roles at the company.

READ: Genprex full steam ahead toward non-small cell lung cancer trials in 2021

“We are pleased to bring together this group of seasoned practitioners in the field of oncology and diabetes to guide and advise Genprex in advancing our clinical development programs,” said Genprex CEO Rodney Varner in a statement. 

 “The Clinical Advisory Board’s experience in clinical trials of cancer and diabetes therapies, combined with their expertise in consulting with small and large biotechnology companies, is invaluable as our drug candidates progress into the clinic.”

The members of Genprex’ Clinical Advisory Board include:

Dr Michael Morse, a professor of medicine in the Division of Medical Oncology and Professor in the Department of Surgery at Duke University Medical Center. His clinical expertise includes management of gastrointestinal malignancies including colon, hepatobiliary, gastroesophageal and pancreatic cancer. His research expertise includes the development of targeted therapies including immunotherapies for cancer. He is editor for Current Opinions in Biologic Therapies and has been the principal investigator of a number of investigator-initiated and industry-supported phase 1 and 2 clinical trials of cancer immunotherapy and therapies for gastrointestinal malignancies.

Col George E. Peoples, MD, served 30 years of active duty as a surgeon and research scientist in the military. He is the founder and director of the Cancer Vaccine Development Program (CVDP), which has been focused on the discovery, development, and clinical testing of cancer vaccines for more than 20 years. Four of the program’s cancer vaccines have been licensed for commercial development. Dr Peoples currently serves as CEO of Cancer Insight LLC, CVDP’s commercial counterpart, which is a boutique cancer immunotherapy Contract Research Organization conducting multiple Phase 1 and 2 clinical trials. He also serves as Professor of Surgery at the Uniformed Services University of the Health Sciences and Professor (adjunct) of Surgical Oncology at MD Anderson Cancer Center (MDACC). 

Dr Andrew Becker is president and founder of Becker Pharmaceutical Consulting, a market research, competitive intelligence, and strategic planning consulting firm that provides analytic and strategy services to companies ranging from small biotechnology and medical device companies up to large multinational pharmaceutical companies on a global basis. He received both his medical degree and PhD in Molecular Pharmacology from Stanford University where his research focused on signaling pathways for the insulin and IGF–1 receptors, deciphering the structure and function of the insulin-degrading enzyme and its role in insulin processing.

Dr William Gannon, Jr serves as Genprex’s vice president of regulatory affairs. He is responsible for managing the company’s regulatory affairs for its upcoming clinical trials. He also will serve as the Medical Monitor, interfacing with medical personnel at trial sites and assisting with US Food and Drug Administration communication throughout the clinical trials. 

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

11 hours, 54 minutes ago